The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 20: 3206 - 3213

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.20.009

Clinical Research

Expression and clinical significance of serum CXCL1 and PRDM5 in lymph node metastasis of progressive gastric cancer

  • Xiaoying DING ,
  • Zhichao DONG ,
  • Jianna MAO ,
  • Changqing GUO ,
  • Aimin. YUE
Expand
  • *.Department of Gastroenterology，Xinxiang Central Hospital，Xinxiang 453000，Henan，China

Received date: 2025-06-27

  Online published: 2025-11-05

Fold

Abstract

Objective To investigate the relationship between serum CXC chemokine ligand 1 （CXCL1） and positive regulatory zone zinc finger protein 5 （PRDM5） levels and lymph node metastasis of progressive gastric cancer and to analyze their predictive value for patients' prognosis. Methods 203 patients with progressive gastric cancer diagnosed in our hospital from June 2020 to March 2023 were selected and divided into the lymph node metastasis group （n = 90） and the no-lymph node metastasis group （n = 113） based on the presence or absence of lymph node metastasis， and the differences in the general information of the two groups were analyzed and compared， and the diagnostic value of CXCL1 and PRDM5 in lymph node metastasis of progressive gastric cancer was analyzed by plotting the ROC curve. Logistic regression was used to analyze the risk factors of lymph node metastasis in patients with progressive gastric cancer. Follow up for 2 years， draw Kapan Meier curves to compare the prognosis of patients with advanced gastric cancer lymph node metastasis at different levels of CXCL1 and PRDM5. Results The CXCL1 level in the lymph node metastasis group was higher than that in the no-lymph node metastasis group， and its PRDM5 level was lower than that in the no-lymph node metastasis group （P < 0.05）.The AUCs for diagnosing lymph node metastasis of progressed gastric cancer were 0.755 and 0.844 for CXCL1 and PRDM5， respectively， and the AUC for the combination of the two was 0.898 （95% CI 0.848 ~ 0.936）. The sensitivity and specificity were 88.89% and 77.88%， respectively （P < 0.05）.Tumor size， differentation degree， serum CEA， serum CA19-9， CXCL1， and PRDM5 levels were all risk factors for lymph node metastasis in patients with progressive gastric cancer （P < 0.05）. The survival time of patients with CXCL1 > 96.13 pg/mL is （15.13 ± 0.85） months， while the survival time of patients with CXCL1 ≤ 96.13 pg/mL is （19.06 ± 0.66） months. The survival time of patients with CXCL1 ≤ 96.13 pg/mL is longer than that of patients with CXCL1>96.13 pg/mL （P<0.05）. The survival time of patients with PRDM>100.85 pg/mL is （18.62 ± 0.69） months， while the survival time of patients with PRDM ≤ 100.85 pg/mL is （14.60 ± 0.78） months. The survival time of patients with PRDM>100.85 pg/mL is longer than that of patients with PRDM ≤ 100.85 pg/mL （P<0.05）. Conclusion The abnormal expression of CXCL1 and PRDM5 is related to lymph node metastasis in patients with progressive gastric cancer， and the combined detection of the two is of high value in the assessment of lymph node metastasis and prognosis in patients with progressive gastric cancer.

Key words： progressive gastric cancer; serum CXC chemokine ligand 1; positive regulatory zone zinc finger protein 5; lymph node metastasis; risk factors; prognosis

Cite this article

Xiaoying DING , Zhichao DONG , Jianna MAO , Changqing GUO , Aimin. YUE . Expression and clinical significance of serum CXCL1 and PRDM5 in lymph node metastasis of progressive gastric cancer[J]. The Journal of Practical Medicine, 2025 , 41(20) : 3206 -3213 . DOI: 10.3969/j.issn.1006-5725.2025.20.009

References

[1] 冯立宗，陈永强，张志鹏，等.基于倾向性匹配对进展期胃癌病人根治性手术联合腹腔热灌注化疗安全性的评估［J］.青岛大学学报（医学版），2023，59（5）：671-674.
[2] ZHAO N， WANG W， JIANG H，et al.Natural products and gastric cancer：cellular mechanisms and effects to change cancer progression［J］.Anticancer Agents Med Chem，2023，23（13）：1506-1518. doi:10.2174/1871520623666230407082955
[3] 张紫涵，陈明明，刘君，等.基于GEPIA数据库分析胃癌和正常组织的差异表达基因及对预后影响［J］.海南医学院学报，2024，30（8）：591-596.
[4] 徐俊，王晓丽，倪静怡，张娣娣. 维迪西妥单抗治疗晚期胃癌的临床疗效及安全性［J］. 实用医学杂志， 2024， 40（20）： 2913-2917.
[5] 周畅，陈伟强，王宇恒 等.癌相关成纤维细胞促进胃癌细胞迁移与侵袭［J］.中山大学学报（医学科学版），2020，41（4）：501-508.
[6] 石琳娜.早期胃癌淋巴结转移评估方法的研究现状［J］.实用肿瘤学杂志，2020，34（3）：286-290.
[7] 李良，谢家存，王志斌，等.淋巴结转移率对Ⅲ期胃癌术后辅助放疗疗效的评估作用［J］.中华放射医学与防护杂志，2021，41（5）：346-352.
[8] 赵成，纪澄华，马雷，等.淋巴细胞与单核细胞比值和进展期胃癌淋巴结转移的相关性［J］.中国现代普通外科进展，2022，25（10）：825-828.
[9] 谢萱虎，王一佳，雷威，等.CXC趋化因子配体5通过程序性死亡蛋白1/程序性死亡蛋白配体1信号通路抑制肺癌肿瘤免疫的作用及机制［J］.中华肿瘤杂志，2022，44（5）：382-388.
[10] SONG H， WANG W， SHEN B，et al.Pretreatment with probiotic Bifico ameliorates colitis-associated cancer in mice：Transcriptome and gut flora profiling［J］.Cancer Sci，2018，109（3）：666-677. doi:10.1111/cas.13497
[11] 张颖.结直肠癌患者血清SDC4，CXCL1水平检测在临床诊断及淋巴结转移评估中的应用价值［J］.现代检验医学杂志，2025，40（1）：116-121.
[12] 李顺来，宋晓琳，周学玲，等.PRDM5通过Notch-1信号通路调控肾细胞癌增殖、侵袭及自噬的分子机制［J］.中国老年学杂志，2024，44（20）：5074-5081.
[13] 刘冠初，丁浩，蒲涛，等.血清PRDM5、GINS4、GNA13联合检测在老年食管癌诊断及淋巴结转移监测中的价值［J］.中国老年学杂志，2025，45（5）：1061-1066.
[14] 陈杰，林超，臧潞，等.局部进展期胃癌新辅助治疗病理学完全缓解预测因素及预后分析的全国多中心研究［J］.中华消化外科杂志，2024，23（3）：371-379.
[15] 陈平，代国坡，史恒峰.基于临床影像学参数构建列线图模型在术前预测胃癌淋巴结转移中的价值［J］.蚌埠医学院学报，2023，48（12）：1721-1725.
[16] KINAMI S， SAITO H， TAKAMURA H.Significance of lymph node metastasis in the treatment of gastric cancer and current challenges in determining the extent of metastasis［J］.Front Oncol，2022，11：806162. doi:10.3389/fonc.2021.806162
[17] TIAN H， NING Z， ZONG Z，et al.Application of machine learning algorithms to predict lymph node metastasis in early gastric cancer［J］.Front Med （Lausanne），2022，8：759013. doi:10.3389/fmed.2021.759013
[18] HUGHES C E， NIBBS R J B.A guide to chemokines and their receptors［J］.FEBS J，2018，285（16）：2944-2971. doi:10.1111/febs.14466
[19] CABRERO-DE LAS HERAS S， MARTíNEZ-BALIBREA E.CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer［J］.World J Gastroenterol，2018，24（42）：4738-4749. doi:10.3748/wjg.v24.i42.4738
[20] 赵津璋.脑胶质瘤中CXCL1的表达及影响肿瘤细胞恶性行为的作用机制研究［D］.佳木斯：佳木斯大学，2021.
[21] ZENG Q， SUN S， LI Y，et al.Identification of Therapeutic targets and prognostic biomarkers among CXC chemokines in the renal cell carcinoma microenvironment［J］.Front Oncol，2020，9：1555. doi:10.3389/fonc.2019.01555
[22] KORBECKI J， BARCZAK K， GUTOWSKA I，et al.CXCL1：Gene，promoter，regulation of expression，mRNA stability，regulation of activity in the intercellular space［J］.Int J Mol Sci，2022，23（2）：792. doi:10.3390/ijms23020792
[23] 周玥莹，曲义坤.过表达趋化因子CXCL1在胃癌中的作用及研究进展［J］.中国医药导报，2024，21（5）：49-52.
[24] PECOT C V， RUPAIMOOLE R， YANG D，et al.Tumour angiogenesis regulation by the miR-200 family［J］.Nat Commun，2013，4：2427. doi:10.1038/ncomms3427
[25] 马梦楚，任媛媛，刘欣.肺腺癌细胞中PRDM5抑癌作用的分子机制初探［J］.天津医科大学学报，2022，28（4）：360-365.
[26] GAO X， LIU H， WANG R，et al.Hsa-let-7d-5p promotes gastric cancer progression by targeting PRDM5［J］.J Oncol，2022，2022（1）：2700651. doi:10.1155/2022/2700651
[27] 苏杰，杨小静，周雪.PR结构域蛋白5过表达对人急性髓系白血病细胞系U937迁移侵袭的影响及其机制［J］.临床内科杂志，2021，38（12）：836-839.
[28] 白杰，张晓宇，康晓宁，等.乳腺癌中PRDM2、PRDM5、PRDM16的甲基化检测及临床意义［J］.临床和实验医学杂志，2019，18（3）：283-287.
[29] TENG J J， ZHAO W J， ZHANG X L，et al.Downregulation of promoter methylation gene PRDM5 contributes to the development of tumor proliferation and predicts poor prognosis in gastric cancer［J］. J Cancer，2021，12（22）：6921-6930. doi:10.7150/jca.59998
[30] ZHANG C， LIU Z， SHENG Y，et al.PRDM5 suppresses oesophageal squamous carcinoma cells and modulates 14-3-3zeta/Akt signalling pathway［J］.Clin Exp Pharmacol Physiol，2022，49（3）：370-379. doi:10.1111/1440-1681.13612
Options
Outlines

/

〈 〉